BRPI0517091B8 - composto 4-hidroxibenzomorfano substituído na posição-3 por carboxamida ou tiocarboxamida - Google Patents

composto 4-hidroxibenzomorfano substituído na posição-3 por carboxamida ou tiocarboxamida

Info

Publication number
BRPI0517091B8
BRPI0517091B8 BRPI0517091A BRPI0517091A BRPI0517091B8 BR PI0517091 B8 BRPI0517091 B8 BR PI0517091B8 BR PI0517091 A BRPI0517091 A BR PI0517091A BR PI0517091 A BRPI0517091 A BR PI0517091A BR PI0517091 B8 BRPI0517091 B8 BR PI0517091B8
Authority
BR
Brazil
Prior art keywords
thiocarboxamide
compound
carboxamide
hydroxybenzomorphan
substituted
Prior art date
Application number
BRPI0517091A
Other languages
English (en)
Inventor
P Wentland Mark
Original Assignee
Rensselaer Polytech Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rensselaer Polytech Inst filed Critical Rensselaer Polytech Inst
Publication of BRPI0517091A publication Critical patent/BRPI0517091A/pt
Publication of BRPI0517091B1 publication Critical patent/BRPI0517091B1/pt
Publication of BRPI0517091B8 publication Critical patent/BRPI0517091B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/26—Benzomorphans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

composto, e, método para tratar uma doença ou condição alterando-se uma resposta mediada por um receptor de opióide. 4-hidroxibenzomorfanos contendo carboxamida ou tiocarboxamida na posição-3, são usados como analgésicos, agentes antidiarréicos, anticonvulsivos, antitussígenos e medicamentos anti-adicção.
BRPI0517091A 2004-11-05 2005-11-03 composto 4-hidroxibenzomorfano substituído na posição-3 por carboxamida ou tiocarboxamida BRPI0517091B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62534804P 2004-11-05 2004-11-05
US60/625,348 2004-11-05
PCT/US2005/039911 WO2006052710A1 (en) 2004-11-05 2005-11-03 4-hydroxybenzomorphans

Publications (3)

Publication Number Publication Date
BRPI0517091A BRPI0517091A (pt) 2008-09-30
BRPI0517091B1 BRPI0517091B1 (pt) 2019-10-08
BRPI0517091B8 true BRPI0517091B8 (pt) 2021-05-25

Family

ID=36128632

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517091A BRPI0517091B8 (pt) 2004-11-05 2005-11-03 composto 4-hidroxibenzomorfano substituído na posição-3 por carboxamida ou tiocarboxamida

Country Status (20)

Country Link
US (7) US7262298B2 (pt)
EP (2) EP2251330B1 (pt)
JP (3) JP5198067B2 (pt)
KR (1) KR101115841B1 (pt)
CN (1) CN101090891B (pt)
AT (1) ATE557006T1 (pt)
AU (1) AU2005304950B2 (pt)
BR (1) BRPI0517091B8 (pt)
CA (1) CA2587074C (pt)
CY (1) CY1112946T1 (pt)
DK (1) DK2251330T3 (pt)
ES (1) ES2387737T3 (pt)
IL (1) IL182983A (pt)
MX (1) MX2007005389A (pt)
NO (1) NO340204B1 (pt)
PL (1) PL2251330T3 (pt)
PT (1) PT2251330E (pt)
RU (2) RU2480455C2 (pt)
SI (1) SI2251330T1 (pt)
WO (1) WO2006052710A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002227135B2 (en) * 2000-10-31 2008-01-03 Rensselaer Polytechnic Institute 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
AU2005304950B2 (en) * 2004-11-05 2010-12-09 Rensselaer Polytechnic Institute 4-Hydroxybenzomorphans
WO2007014137A2 (en) 2005-07-21 2007-02-01 Rensselaer Polytechnic Institute 8-carboxamido-substituted-2 , 6-methano-3-benzazocines and 3 - carboxamido- substituted morphanes as opioid receptor binding agents
WO2008137672A1 (en) 2007-05-04 2008-11-13 Mallinckrodt Inc. Improved process for the preparation of 6-alpha-hydroxy-n-alkylated opiates
EP2167505B1 (en) 2007-07-17 2012-11-28 Mallinckrodt LLC Preparation of n-alkylated opiates by reductive amination
BRPI0815020A2 (pt) 2007-08-09 2015-03-10 Rensselaer Polytech Inst Composto, e, métodos de aliviar um efeito colateral de um opiato em um paciente que recebeu um opiato, e de melhorar função do intestino pós-operatório em um paciente que se submeteu a cirurgia.
NZ607842A (en) 2008-09-30 2013-12-20 Mallinckrodt Llc Processes for the selective amination of ketomorphinans
US8946419B2 (en) 2009-02-23 2015-02-03 Mallinckrodt Llc (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
CA2754984C (en) * 2009-03-19 2018-06-26 Alkermes, Inc. Morphinan derivatives with high oral bioavailability
US20100261906A1 (en) * 2009-04-09 2010-10-14 Mallinckrodt Inc. Preparation of 6-Keto, 3-Alkoxy Morphinans
ES2598496T3 (es) 2009-06-11 2017-01-27 Mallinckrodt Llc Preparación de 6-alfa-amino morfinanos N-sustituidos por transferencia de hidrógeno catalítico
US8471023B2 (en) 2009-06-11 2013-06-25 Mallinckrodt Llc Reductive amination of 6-keto normorphinans by catalytic hydrogen transfer
NZ600379A (en) * 2009-12-04 2014-05-30 Alkermes Pharma Ireland Ltd Morphinan derivatives for the treatment of drug overdose
US8436175B2 (en) 2010-03-22 2013-05-07 Rensselaer Polytechnic Institute Carboxamide bioisosteres of opiates
PL2563793T3 (pl) * 2010-04-29 2015-03-31 SpecGx LLC Wytwarzanie nasyconych związków ketonowych morfinanu o niskiej zawartości metalu
WO2012005795A1 (en) 2010-07-08 2012-01-12 Alkermes, Inc. Process for the synthesis of substituted morphinans
SI2608670T1 (sl) 2010-08-23 2019-04-30 Alkermes Pharma Ireland Limited Postopki za zdravljenje pridobivanja teže, ki je posledica uporabe antipsihotičnih zdravil
WO2012138888A1 (en) 2011-04-05 2012-10-11 Alkermes, Inc. Process for the synthesis of quaternary amine compounds
BR112013031420A2 (pt) 2011-06-09 2016-08-16 Mallinckrodt Llc "processo para preparar um 6-amino morfinano, composição que o compreende e composição compreendendo um composto intermediário"
AU2012275181B2 (en) 2011-06-29 2016-04-07 Alkermes, Inc. Peripherally acting opioid compounds
CN103917543A (zh) 2011-09-08 2014-07-09 马林克罗特有限公司 在不分离中间体的情况下制备生物碱
EP3415148A1 (en) 2011-12-15 2018-12-19 Alkermes Pharma Ireland Limited Compositions of buprenorphine and mu-opioid receptor antagonists
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
EP3003311A2 (en) 2013-05-24 2016-04-13 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
AU2014268361B2 (en) 2013-05-24 2018-09-06 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
CN110352055A (zh) * 2017-03-02 2019-10-18 株式会社三和化学研究所 酒精使用障碍的治疗药物
CN107089948B (zh) * 2017-04-28 2020-07-17 云南大学 吗吩衍生物及其制备方法和应用
CN111978252A (zh) * 2019-05-21 2020-11-24 复旦大学 手性苯并吗吩烷类衍生物及其制备方法和在药学上的应用
CN113248435B (zh) * 2020-02-13 2024-06-04 上海翰森生物医药科技有限公司 3-甲酰胺基-4-羟基纳曲酮氘代衍生物、其制备方法及其在医药上的应用
CN111205151B (zh) * 2020-02-29 2021-03-05 深圳市祥根生物科技有限公司 一种布洛芬杂质i的环保制备方法
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet
KR102663533B1 (ko) * 2021-11-09 2024-05-08 백미선 레이저 치료기기용 온냉각장치

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032529A (en) * 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
US3957793A (en) * 1974-09-20 1976-05-18 Sterling Drug Inc. Hydroxyiminobenzazocines
US4205171A (en) * 1976-01-12 1980-05-27 Sterling Drug Inc. Aminomethanobenzazocines and nitromethanobenzazocines
US4373139A (en) * 1979-04-30 1983-02-08 Motorola, Inc. Detectors
US4649200A (en) * 1986-05-08 1987-03-10 Regents Of The University Of Minnesota Substituted pyrroles with opioid receptor activity
EP0632041A1 (en) 1993-07-01 1995-01-04 Katholieke Universiteit Nijmegen New morphine derivatives having improved analgesic and narcotic properties
PL327943A1 (en) 1996-01-10 1999-01-04 Smithkline Beecham Spa Condensed heterocyclic derivatives of morphonoide (ii)
AU2002227135B2 (en) * 2000-10-31 2008-01-03 Rensselaer Polytechnic Institute 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
AU2003281060A1 (en) * 2002-07-16 2004-02-02 Rensselaer Polytechnic Institute Process for conversion of phenols to carboxamides via the succinimide esters
AU2005304950B2 (en) * 2004-11-05 2010-12-09 Rensselaer Polytechnic Institute 4-Hydroxybenzomorphans

Also Published As

Publication number Publication date
SI2251330T1 (sl) 2012-09-28
RU2010147915A (ru) 2012-05-27
US20240092740A1 (en) 2024-03-21
JP2016020364A (ja) 2016-02-04
MX2007005389A (es) 2007-12-07
NO20072839L (no) 2007-08-03
JP2013067636A (ja) 2013-04-18
RU2007120759A (ru) 2008-12-10
EP1817291A1 (en) 2007-08-15
ES2387737T3 (es) 2012-10-01
BRPI0517091A (pt) 2008-09-30
CA2587074A1 (en) 2006-05-18
AU2005304950B2 (en) 2010-12-09
CA2587074C (en) 2012-09-04
JP2008519035A (ja) 2008-06-05
US8680112B2 (en) 2014-03-25
CN101090891B (zh) 2012-08-01
IL182983A (en) 2012-06-28
JP5198067B2 (ja) 2013-05-15
PL2251330T3 (pl) 2012-12-31
IL182983A0 (en) 2007-08-19
RU2480455C2 (ru) 2013-04-27
KR101115841B1 (ko) 2012-03-09
JP6058981B2 (ja) 2017-01-11
DK2251330T3 (da) 2012-08-06
EP2251330B1 (en) 2012-05-09
WO2006052710A1 (en) 2006-05-18
US20150011768A1 (en) 2015-01-08
US7262298B2 (en) 2007-08-28
PT2251330E (pt) 2012-07-20
KR20070085723A (ko) 2007-08-27
US20140148475A1 (en) 2014-05-29
US20060111384A1 (en) 2006-05-25
AU2005304950A1 (en) 2006-05-18
CY1112946T1 (el) 2016-04-13
US20130231361A1 (en) 2013-09-05
ATE557006T1 (de) 2012-05-15
CN101090891A (zh) 2007-12-19
RU2415131C2 (ru) 2011-03-27
US20160075658A1 (en) 2016-03-17
NO340204B1 (no) 2017-03-20
US20070238748A1 (en) 2007-10-11
EP2251330A1 (en) 2010-11-17
BRPI0517091B1 (pt) 2019-10-08
US8802655B2 (en) 2014-08-12

Similar Documents

Publication Publication Date Title
BRPI0517091B8 (pt) composto 4-hidroxibenzomorfano substituído na posição-3 por carboxamida ou tiocarboxamida
BRPI0408247A (pt) usos de antagonistas e agonistas de il-23 e reagentes relacionados
ECSP088461A (es) Composiciones farmacéuticas que contienen buprenorfina
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
NO20052739D0 (no) CCR5-antagonister som medikamenter
ZA200502247B (en) Selected CGRP antagonists, method for production and use thereof as medicament.
BRPI0510777A (pt) indazóis substituìdos, composições que os contêm, processo de produção e utilização
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
IL168056A0 (en) Selected cgrp antagonists, method for production and use thereof as medicament
ATE469895T1 (de) Cgrp-rezeptorantagonisten
MX2019012598A (es) Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
MY149803A (en) Markup based extensibility for user interfaces
CL2003002277A1 (es) Composicion farmaceutica inyectable, de deposito de liberacion prolongada, que comprende un agente beneficioso disuelto o disperso en un gel constituido por un polimero bioerosionable y biocompatible; y un solvente.
ATE516301T1 (de) Y2-selektive rezeptoragonisten für therapeutische eingriffe
WO2008018796A3 (en) Viscoelastic aqueous gels comprising microspheres
BRPI0506888A (pt) composições de suplemento lìquido compreendendo um ou mais medicamentos
FR2886851B1 (fr) Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
HRP20080463T3 (en) Crystallized polyethylene terephthalate, which contains silicone, and process for its preparation
BRPI0718469A2 (pt) Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto.
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
DK1220852T3 (da) Substituerede diazepaner
BRPI0611526A2 (pt) composição tópica contendo gelatina
FR2886852B1 (fr) Composition a base d'une avermectine et d'hydrocortisone notamment pour le traitement de la rosacee
RS51534B (en) NEW COMPOUND OF SINUSOID IF CURRENT INHIBITORS AND CALCIUM INHIBITOR AND PHARMACEUTICAL MIXTURE CONTAINED BY IT
BR0313307A (pt) Antagonistas do receptor de mcp-1 e método para a sua utilização

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/10/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/10/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/11/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed